NEW YORK (CNN/Money) - An FDA advisory panel voted to recommend Tarceva, a lung cancer treatment, in conjunction with another drug to treat pancreatic cancer.

The panel voted 10-3 to recommend Tarceva, which is currently used to treat non-small cell lung cancer, the uncontrolled growth of malignant cancer cells, in conjunction with another drug, gemcitabine, which is used to treat metastatic pancreatic cancer.

Tarceva, also known as erlotinib, is developed by OSI Pharmaceuticals (Research) and Genentech (Research). The drug was approved by the FDA in November, 2004.

Pancreatic cancer is the fourth leading cause of cancer death in the United States, killing some 32,000 people per year.

The Food and Drug Administration usually follows the advice of its panels, which generally comes about one month before the agency review.

The read about another panel vote on a cancer drug, click here.